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Hypoglycemia is a common metabolic problem in the neonatal period, but the definition of hypoglycemia is still controversial [1]. Although neuroglycopenic response as 
increased cerebral blood flow or abnormal evoked potentials is 
demonstrated in neonates at levels below 30-45 mg% [2,3], there 
is no defined “safe glucose” level above which there is no risk 
for developmental delay [4]. Guidelines recommend different 
cut-offs varying from 25 to 60 mg% for the management of 
hypoglycemia in neonates without a stringent evidence [1,5-7].
Glucose is primary substrate for brain, especially in infants, 
to protect brain development [4]. Studies on neurodevelopmental 
outcomes after neonatal hypoglycemia have conflicting 
results [8,9]. Several confounders such as gestational age, birth 
weight, sepsis, respiratory distress, duration of ventilation, 
asphyxia, intra-cranial bleed, the presence of ductus arteriosus, 
and socio-economic status influence the outcome of preterm 
neonate [10,11]. The recent systematic review suggests that 
preterm and growth-restricted neonates should be the prime 
targets for follow-up studies on neonatal hypoglycemia, because 
of impaired glycogenolysis and gluconeogenesis, and inadequate 
alternate fuels [10].
This study was conducted in high-risk neonates of birth weight 
<2000 g, to find the effect of different levels of blood glucose (BG) 
in the first 3 days of life on their neurodevelopmental outcome 
at 1 year of corrected age (CA) as assessed by Development 
Assessment Scale for Indian Infants (DASII).
METHODS
This prospective cohort study was conducted in a tertiary level 
neonatal unit in south India. Intramural neonates of birth weight 
<2000 g born from September 2009 to August 2010 were enrolled 
for study and eligible infants were followed until 1 year CA in 
Neonatal Follow-up Clinic (NFC). Prior ethical approval was 
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obtained. The unit’s protocol is to admit and treat neonates of birth 
weight <2000 g in neonatal intensive care unit (NICU). Parents 
of eligible neonates were approached soon after admission for 
consent and enrolment. Neonates with major malformations, 
severe asphyxia (5 min APGAR <3), meningitis, and severe 
degree of intra-ventricular bleed were excluded.
Maternal details, including pregnancy complications, and 
ante-natal steroids were obtained from medical records. Maternal 
education and details for socio-economic status scale [12] were 
obtained by a short interview with mother. Gestational age was 
assessed by first trimester scans (n=42) and last menstrual period 
(n=87) if early scans were unavailable. Neonates were classified 
as small, appropriate (10-90th centile) and large for gestation 
based on Lubchenco charts [13].
Respiratory support, surfactant, fluid management, and 
ongoing care were based on unit’s protocol. Duration of 
ventilation, parenteral nutrition, apnea, blood culture, patent 
ductus arteriosus (PDA), inotropes, peak bilirubin level, intra-
ventricular hemorrhage, necrotizing enterocolitis (NEC), packed 
cell transfusion, seizures, and chronic lung disease were some of 
the other variables. Hearing screen, retinopathy of prematurity 
screen, and thyroid screening reports were noted. Restricted 
transfusion guideline is the unit’s protocol [14]. The cut-off taken 
for hypoxia, hyperoxia, hypocarbia, and hypercarbia was 50, 100, 
25, and 60 mmHg, respectively [15-17].
Neonates were given feeds or intra-venous fluids after 
admission and BG was measured within 2 h and then 6 hourly. 
At least 12 measurements were done in the first 72 h. Mean and 
lowest BG was calculated. Further BG was measured based on unit 
protocol. Hypoglycemia was managed by standard protocol [18]. 
Symptomatic neonates or if BG <25 mg%, glucose infusion was 
started at 6-8 mg/kg/min, following a mini-bolus. If a neonate 
on fluids had BG <40 mg%, glucose infusion was increased by 
2 mg/kg/min. Asymptomatic neonate with BG 25-40 mg% were 
given feed, and if repeat BG, measured in 30 min was <40 mg%, 
glucose infusion was started.
BG was measured by Accu-chek active glucometer, which is 
of ISO-15197 standard [19]. Pre-warmed heel of a neonate was 
cleaned with sprit and after drying, skin puncture was done in 
posterolateral aspect by lancet [20]. A good drop of blood touched 
the edge of glucometer strip and BG was noted. Whenever BG 
measured by glucometer was ≤50 mg%, venous blood 0.5 ml was 
sent to laboratory for “hexokinase” analysis and BG level thus 
obtained was taken for study [21]. Glucometer measurement and 
sample collection were done by trained nursing staff or residents 
on duty.
Follow-up
Babies were discharged when they had no ongoing problems, 
weighed ≥1400 g and gaining weight on paladay or direct feeds. 
Follow-up in NFC was at least fortnightly to monthly until 
3 months CA. All infants received early intervention therapy, 
iron, calcium, and vitamin supplements. Neuro-motor assessment 
and development assessments at 3, 6, and 9 months CA were done 
by Amiel-Tison and Denver II methods. A total score of ≥5 was 
considered abnormal neuro-motor assessment and development 
delay was considered if infant failed to do any 2 items for 
age [22,23].
The primary outcome of the study was the developmental 
assessment by DASII at 12 months of age, which is the Indian 
adaptation of Bayley Scales [24]. Age placement of the total 
score gives infant’s motor and mental developmental age (DA) in 
months. Infants who had at least 2 of the 3 visits at 3, 6, 9 months 
and also completed DASII assessment at 12 months of CA were 
considered to have adequate follow-up and eligible for analysis. 
Motor and mental development quotient (DQ) was calculated. 
Hearing and visual evaluation, done at 8-9 months, were noted. 
Poor composite outcome was defined by motor or mental DQ 
below 85% or requirement of hearing aids or impaired vision or 
cerebral palsy as defined by persistent tone abnormalities.
Sample Size and Statistical Analysis
Sample size was calculated using nMaster2.0 software. As a pilot 
study, DASII done at 1 year CA, in 10 infants of birth weight 
<2000 g showed their mean motor and mental age as 11.01±0.71 
and 11.46±0.61 months, respectively. We hypothesized that at CA 
of 1 year, the DA of infants with low BG levels will be within 
0.5 months, when compared to those with normal BG levels. To 
find a difference of 0.5 months in DA, 63 infants was required 
in each group at a power 0.8, Type I error 0.05 and two-sided 
significance.
Statistical analysis was performed using SPSS17.0 for 
windows. Continuous data were analyzed by t-test when normally 
distributed or else by Mann–Whitney test. Categorical data were 
analyzed using Chi-square test or Fisher exact test. Pearson 
coefficient was used to find a correlation between BG levels and 
developmental age. Multinominal logistic regression analysis 
was performed to find the adjusted odds ratio (OR).
RESULTS
During the period from September 2009 to August 2010, 262 
intramural neonates of birth weight <2000 g were admitted to 
NICU. The details of enrolment and follow-up are as mentioned 
in trial flow (Fig. 1). Of the154 infants in follow-up, 129 infants 
(106 singletons, 23 from twin gestation) had adequate follow-up 
and eligible for analysis.
The mean birth weight and gestation of 129 infants was 
1493.5±305.3 g and 32.8±2.5 weeks, respectively. There were 31 
very preterm (<32 weeks), 54 moderate preterm (32-33 weeks), 
39 late preterm (34-36 weeks), and 5 were term infants (37-
42 weeks) and the majority were appropriate for gestation 
(76%). Among 1596 BG measurements done by glucometer, 185 
readings (11.5%) were ≤50%, but hexokinase method confirmed 
only 153 measurements as ≤50 mg%. The distribution of BG at 
different ages in first 72 h is shown in Fig. 2. The median number 
of BG measurements done in a neonate in first 72 h was 12 
(range 11-19).
Vol 3 | Issue 4 | Oct - Dec 2016 Indian J Child Health 276
Chandrasekaran et al. Blood glucose in high-risk neonates and development outcome
Mean BG at 0-2 h was 52.1 mg% and it was significantly lower 
compared to any other age. 5th and 10th centile of BG during initial 
72 h were 41 and 51 mg%, respectively. Comparison of infants 
who had BG below 10th centile, 51 mg% (n=60) and those who 
had all BG above 51 mg% (n=69) showed no significant difference 
in demographic profile, maternal factors and morbidities of the 
neonates; except for BG <51 mg% after 72 h, which occurred while 
tapering intravenous fluids (Table 1). Maternal education level 
and socio-economic status were also similar in two groups. The 
median number of episodes of BG <51 mg%, in 60 infants was 3 
and 8 infants had BG <51 mg% only in initial screen. Symptomatic 
hypoglycemia was seen in 13 neonates and the most common 
symptom was jitteriness followed by lethargy, but none had seizures.
Follow-up at 3, 6, 9 and 12 months CA was done in 115, 119, 
117 and 129 infants. At 6 and 9 months CA, abnormal neuro-
motor assessment and developmental delay were seen in 19, 25 
infants and 22, 17 infants, respectively. Both abnormal neuro-
motor assessment and developmental delay at 9 months CA 
were seen in 12 infants, among them 8 infants had symptomatic 
hypoglycemia. The mean weight and head circumference at 
1 year CA was 8.5±0.78 kg and 44.2±0.5 cm, respectively. The 
mean motor and mental DA assessed by DASII at 1 year CA 
was 11.3±0.68 and 11.5±0.48 months. Motor and mental DA 
of extremely low birth weight infants were significantly lower 
(Table 2). Maternal education level and socio-economic status 
had no significant effect on motor and mental DA.
Figure 1: Trial flow – enrollment and follow-up details
Figure 2: Box-Whisper plot: Blood glucose levels at different ages 
in first 72 h
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A significant difference in motor and mental DA at different 
levels of lowest BG was observed (Table 2). The lowest BG level 
of neonate had a significant positive correlation with their motor 
and mental DA assessed by DASII. The Pearson coefficient for 
motor and mental age was r=0.26 (p=0.003), r=0.2 (p=0.035), but 
for mean BG level, Pearson coefficient for motor and mental age 
was r=0.1 (p=0.2), r=0.08 (p=0.36), respectively.
The difference in mean motor and mental DA until a level 
of 50 mg% for lowest BG is significant, but at higher levels, 
there is no significant difference (Table 2). The mean motor 
DA by DASII at 1 year CA, when any BG <51 mg% (n=60) 
and when all BG >50 mg% (n=69) in first 72 h was 11.1±0.8 
and 11.47±0.6 months, respectively. Similarly, mental DA by 
DASII in these groups was 11.36±0.52 and 11.59±0.42 months, 
respectively. Infants with symptomatic hypoglycemia had poor 
outcome compared to asymptomatic infants, but the number of 
episodes had no significant effect.
Poor composite outcome was seen in 12 infants and out of 
them, 8 (75%) had BG <51 mg%. Both motor and mental DQ 
<85% was seen in 11 infants and one had only mental DQ <85%. 
Impaired hearing or vision and cerebral palsy were not seen in 
any infants. Birth weight and gestation-adjusted OR for poor 
composite outcome when lowest BG was below 10th centile (<51 
mg%) was 2.83 (confidence interval [CI]=0.65-12.3) and adjusted 
OR for other variables is shown in Table 3.
DISCUSSION
Ever since the landmark studies on neonatal hypoglycemia by 
Cornblath et al. [25], many studies have been done; however, 
the safe level above which there is no long-term or short-
term risk is still not known [26]. Even the pediatric endocrine 
society recently recommended maintaining BG above 50 mg% 
in at risk infants until we get further evidence [27]. In this 
study also, we found a significantly lower DA at 1 year CA 
in infants when their lowest BG level was in lower range. 
But after adjusting for birth weight and gestation, there was 
no significant difference in the composite outcome. Several 
co-morbid factors as prematurity, birth weight, sepsis, 
shock, apnea, growth restriction, ventilation, social factors, 
Table 1: Maternal and infant variables in relation to BG levels
Variables Lowest BG below 10th centile 51 mg% 
(n=60)
Lowest BG above 10th centile >50 mg% 
(n=69)
p value
Gestational age in weeks* Mean (SD) 33.2 (2.7) 32.5 (2.4) 0.283
Birth weight in grams* Mean (SD) 1506.3 (338) 1482.4 (275) 0.66
Head circumference at birth in cm* Mean (SD) 29.3 (1.7) 29.5 (1.5) 0.61
Male† n (%) 32 (53) 36 (52) 0.895
Small for gestation† n (%) 18 (30) 13 (19) 0.14
Maternal age in years* Mean (SD) 26.7 (3.8) 26.4 (4.6) 0.65
Maternal PIH† n (%) 22 (36.6) 30 (43.5) 0.43
Apgar scores at 5 min‡ Median (range) 8 (4-9) 9 (6-9) 0.22
Adequate AS in <34 weeks† 21 of 37 eligible 28 of 48 eligible 0.826
Normal delivery† n (%) 27 (45) 36 (52.2) 0.42
Extensive resuscitation§ n (%) 3 (5) 1 (1.45) 0.39
Ventilation required† n (%) 28 (46.6) 31 (45) 0.84
Duration of ventilation (days)* Mean (SD) 5.1 (5.7) 5.1 (3.67) 0.16
Hypoxia§ n (%) 1 (1.6) 4 (5.8) 0.23
Hypocarbia† n (%) 11 (18.3) 15 (21.7) 0.63
Hypercarbia§ n (%) 4 (8.7) 6 (6.7) 0.67
Hyperoxia† n (%) 8 (13.3) 13 (18.8) 0.40
Peak bilirubin levels in mg%* Mean (SD) 11.4 (2.5) 11.5 (2.5) 0.89
Seizures§ n (%) 1 (1.6) 1 (1.5) 0.92
Apnea† n (%) 11 (18.3) 13 (18.8) 0.94
Ductus treated† n (%) 15 (25) 20 (29) 0.74
Inotropes required† n (%) 8 (13.3) 6 (6.7) 0.40
Packed cell transfusion† n (%) 9 (15) 12 (17.3) 0.714
Culture positive sepsis§ n (%) 2 (3.3) 2 (2.9) 0.89
IVH Grade I or II † n (%) 8 (13.3) 6 (6.7) 0.76
Parenteral nutrition† n (%) 17 (28.3) 18 (26) 0.74
Feed intolerance n (%) 14 (23.3) 9 (13) 0.13
Glucose levels ≤50 mg% after 72 h§ 6 (10) 0 0.01
*Student t-test, †Chi-square test, ‡Mann–Whitney test, §Fisher exact test. ventilation includes both CPAP and invasive ventilation, BG: Blood glucose, IVH: Intra-ventricular 
hemorrhage based on sonogram, AS: Antenatal steroids, CPAP: Continuous positive airway pressure, SD: Standard deviation
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hyperbilirubinemia, PDA, NEC, confound the outcome studies 
on neonatal hypoglycemia [28,29].
The outcome of neonatal hypoglycemia is quite conflicting, 
because of differences in inclusion criteria, study design, accuracy 
Table 3: OR and unadjusted OR for composite outcome
Variable n (%) OR (95% CI) aOR (95% CI) P
Poor composite outcome 
(n=12)
Good composite outcome 
(n=117)
Lowest BG <51 mg% 8 (66.6) 52 (44.4) 2.3 (0.7-7.3) 2.83 (0.65-12.3) 0.18
Ventilation >3 days 8 (66.6) 27 (23.1) 6.6 (1.9-23.8) 3.12 (0.86-15.4) 0.08
SGA 6 (50) 25 (21.4) 3.6 (1.1-12.4) 2.7 (0.72-11.6) 0.35
Symptomatic and BG <51 mg%* 3 (37.5) 10 (15.2) 2.5 (0.5-12.3) 1.8 (0.3-14) 0.87
BG <51 mg% and ≥3 episodes* 4 (50) 21 (41.2) 1.5 (0.33-6.7) 1.2 (0.57-4.9) 0.74
*Only for infants with BG <51 mg% (n=60, 8 infants had poor composite outcome). OR: Odds ratio, aOR: Adjusted odds ratio (adjusted for birth weight and gestational age), 
CI: Confidence interval, SGA: Small for gestation, BG: Blood glucose
Table 2: Motor DA and mental DA by DASII assessment at 1 year corrected age
Variable Motor DA by DASII in months 
Mean (SD)
p value Mental DA by DASII in months 
Mean (SD)
p value
Gestational age*
≤32 weeks (54) 11.25 (0.81) 0.37 11.42 (0.56) 0.24
>32 weeks (75) 11.36 (0.56) 11.52 (0.4)
Birth weight†
<1000 g (9) 10.1 (0.85) 0.02 10.6 (0.46) 0.04
1000-1499 g (54) 11.3 (0.65) 11.3 (0.65)
1500-1999 g (66) 11.5 (0.5) 11.6 (0.4)
Male (68)* 11.3 (0.7) 0.98 11.5 (0.5) 0.82
Female (61) 11.3 (0.65) 11.5 (0.5)
SGA (31)* 11.1 (0.75) 0.08 11.37 (0.5) 0.12
AGA (98) 11.4 (0.64) 11.55 (0.45)
Not ventilated† (70) 11.47 (0.47) 0.01 11.51 (0.42) 0.07
Ventilation <3 days (24) 11.31 (0.42) 11.33 (0.42)
Ventilation >3 days (35) 10.9 (0.9) 11.32 (0.62)
Socio-economic status†
Upper (25) 11.23 (0.85) 0.79 11.51 (0.58) 0.76
Middle (73) 11.34 (0.65) 11.45 (0.46)
Lower (31) 11.33 (0.61) 11.52 (0.43)
Lowest BG level†
<30 mg% (14) 10.92 (0.83) 0.015 11.22 (0.62) 0.05
30-39 mg% (33) 11.12 (0.86) 11.35 (0.52)
40-50 mg% (13) 11.43 (0.34) 11.37 (0.39)
51-59 mg% (37) 11.54 (0.46) 11.49 (0.36)
>60 mg% (32) 11.6 (0.36) 11.54 (0.42)
Lowest BG level mg%*
<51 (60) versus >50 (69) 11.06 (0.84), 11.46 (0.51) 0.001 11.34 (0.54), 11.56 (0.41) 0.004
<61 (97) versus >60 (32) 11.3 (0.7), 11.49 (0.63) 0.47 11.45 (0.47), 11.57 (0.48) 0.48
BG <51 mg% (60)*
Symptomatic (13) 10.49 (1.03) 0.01 11.05 (0.57) 0.03
Asymptomatic (47) 11.35 (0.59) 11.46 (0.49)
Episodes BG <51 mg% *
<3 episodes (35) 11.14 (0.74) 0.62 11.48 (0.5) 0.26
≥3 episodes (25) 11.23 (0.68) 11.33 (0.45)
*Student t-test, †ANOVA test. DA: Developmental age, BG: Blood glucose, DASII: Developmental Assessment Scales for Indian Infants
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of measured glucose, cut-off for hypoglycemia, age at follow-up 
duration, and timing of hypoglycemia [10]. Hypoglycemia 
in initial days of life is hypoketotic hypoglycemia with 
hyperinsulinism and preserved hepatic glycogen reserves in term 
and preterm infants [30]. Transitional hypoglycemia is considered 
a maturational process, but Kaiser et al. recently reported lower 
proficiency in language and mathematics at 10 years of age for 
infants who had only one BG <45 mg% at 3 h of age [31].
Brand et al. found no effect of transient hypoglycemia 
(plasma glucose <40 mg%) on outcome at 4 years, in large for 
gestation infants of non-diabetic mother by Denver scale and 
behavior checklist [8], but Haworth et al. reported a poor outcome 
at 3-4 years in infants of diabetic mother with hypoglycemia 
<20 mg% [9].
In this study, we found lower development outcome at 1 year 
CA when any BG was ≤50 mg% in first 72 h. In a similar high-
risk group, Lucas et al. found a higher risk of developmental 
delay at 18 months CA, when plasma glucose was <47 mg% [27]. 
They also reported reduced mental score by 14 points (CI=22-6) 
and reduced motor score by 13 points (CI=20-5) if hypoglycemia 
occurred on 5 separate days [27]. In growth retarded infants, 
Duvanel et al. also reported delayed psychometric scores at 
5 years when recurrent episodes of moderate hypoglycemia (BG 
<47 mg%) occurred [32]. The number of episodes of BG level 
≤50 mg% had no significant effect on outcome in our study.
Duvanel et al. also reported a smaller head size at 5 years in 
infants who had neonatal hypoglycemia, which was not seen in 
our study [32]. There was a significant difference in DA at 1 year, 
between symptomatic and asymptomatic neonates with BG 
≤50 mg% and the adjusted OR for poor composite outcome was 
2.83 (0.65-12.3). Koivisto et al. and Singh et al. have reported 
poorer outcomes in symptomatic hypoglycemic infants [33,34]; 
but in our study, no neonate had hypoglycemic seizures and the 
outcomes of symptomatic and asymptomatic infants were similar. 
We found that BG level in the first 72 h of life did not influence the 
composite outcome at 1 year CA after adjusting for confounding 
variables. But Lucas et al., in a larger sample found that the 
number of episodes of hypoglycemia independently predicted the 
outcome at 18 months [27].
In our study, the mean BG in the first 2 h (52.2±19.7 mg%) and 
levels in first 72 h are comparable to those reported by Srinivasan 
et al. and Heck and Erenberg in term infants [35,36]. The 5th and 
10th centile (41 and 51 mg%) in the present study is higher than 
those reported in term infants [32,33], which may be due to early 
initiation of fluids or feeds based on the clinical condition. The 
incidence of hypoglycemia (≤50 mg%) in this study was 46.5%. In 
similar high risk groups, the reported incidence by Lucas et al. and 
Duvanel et al. was 66% and 64% [27,32]. We found no difference 
in maternal and infant characteristics between infants with BG 
≤50 mg% or >50 mg%. However, Lucas et al. found male sex, 
small for gestation, maternal preeclampsia, 5 min Apgar score <5, 
as risk factors for hypoglycemia in high-risk infants [27].
The merits of this study are the prospective data collection 
and accounting for various neonatal factors, which may influence 
the developmental outcome and their regular follow-up in 
high-risk clinic. The limitations include 16% loss to follow-up, 
the main reason being residence far away (>100 km) and financial 
compensation for visits was not possible. Imaging studies could 
not be done due to logistic reasons. Follow-up studies from India 
and developing countries have reported dropout rates of 30-60% 
at 1-3 years [37,38]. We would definitely need a larger sample 
size and longer follow-up to identify academic or behavioral 
problems.
CONCLUSION
We found a positive correlation of lowest BG level in high-risk 
neonates of birth weight <2000 g with their development outcome 
at 1 year CA. Although, high-risk infants with BG level ≤50 mg% 
are at added risk for delayed development at 1 year CA. Various 
other morbidities determine their outcome and larger studies are 
needed to make evidence-based recommendations on neonatal 
hypoglycemia.
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